MiNK Therapeutics
Market cap $47.7M 5.1M shares (10-Q, Nov 6, 2026) × $9.29 close Nov 17, 2026
Most recent annual filing: 2026-03-31
- agenT-797 topline2H 2027agenT-797 topline, 2H 2027, thesis-defining
- agenT-797 GEJ readout2H 2027agenT-797 GEJ readout, 2H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
MiNK-413
- Undisclosed indication
MiNK-215
PRAME-iNKT
- Undisclosed indication
Technology platforms
CARDIS
Hybrid phage and mammalian display technology enabling highly selective and functionally optimized CAR, TCR, and bispecific engager discovery. Designed to produce candidates with improved pharmaceutical quality, minimal off-target toxicity, and reduced immunogenic risk through fully human antibody fragments. Applied to iNKT cell engineering for oncology and immune-mediated diseases.
allogeneic iNKT
MiNK's allogeneic invariant natural killer T (iNKT) cell therapy platform combining off-the-shelf unmodified cell therapy (agenT-797) with next-generation engineered CAR-iNKT candidates (e.g., MiNK-215); designed for scalable, cryopreserved delivery across cancer, immune-mediated diseases, and pulmonary immune failure
Targets: FAP, NKG2D
Capital (as filed)
- Cash
- $7.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$1.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $7.5M cash per the update of Nov 11, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-11 UPDATE: MiNK Therapeutics (INKT) - The Binary Slips Again 🔒 Paid
- 2026-08-07 UPDATE: MiNK Therapeutics (INKT) - The First Patients Are Alive 🔒 Paid
- 2026-06-13 MiNK Therapeutics (INKT) - Scientific Deep Dive for agenT-797 and the iNKT Cell Pipeline
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on MiNK Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-13 Watch MiNK Therapeutics (INKT) - Scientific Deep Dive for agenT-797 and the iNKT Cell Pipeline Differentiated off-the-shelf iNKT biology and a cleanly randomized ARDS readout in a no-approved-therapy market make this worth watching, but going-concern balance sheet, Agenus control, absent lead-asset composition-of-matter IP, and zero specialist smart money keep it off a Buy until H2 2026 data de-risks the platform.
- 2026-08-07 Watch UPDATE: MiNK Therapeutics (INKT) - The First Patients Are Alive Encouraging early safety and biomarker data from the ARDS trial are positive but uncontrolled and without a randomized comparison; the binary catalyst has slipped to early 2027, adding two quarters of dilution risk with no change in the fundamental concerns.
- 2026-11-11 Watch UPDATE: MiNK Therapeutics (INKT) - The Binary Slips Again The ARDS readout has slipped a second time to 2H2027, cash is down to $7.5M with a raise now explicitly on the table, and the endpoint has shifted from survival to ECMO prevention; the science hasn't worsened but the structure has, keeping the stock on watch with no new buying until a U.S. patient is dosed, FDA aligns on the adaptive design, and a raise clears.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The University of Wisconsin-Madison has informed us that it expects the first patient to be scheduled for dosing by December 2026.”
matched to agenT-797 · topline data
-
-
-
“Preliminary data are expected in the second half of 2026.”
matched to agenT-797 · topline data
-
-
-
“Preliminary data are expected in the second half of 2026.”
matched to agenT-797 · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (20)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1
- Nov 12, 202610-QQuarterly report
- Nov 11, 2026ReleaseMiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies→ BD updateMiNK's Q3 drops three genuine thesis movers: ARPA-H selected agenT-797 for a room-temperature cell-therapy program (up to $87M program-wide), the named-patient program generated the company's first-ever product revenue, and the randomized ARDS readout slipped to 2H2027 — adding a full year to the binary-event clock.
- Nov 6, 2026ReleaseMiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
- Nov 2, 2026ReleaseMiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
- Oct 2, 2026ReleaseMiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
- Sep 30, 2026ReleaseMiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
- Aug 13, 2026ReleaseMiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung InjuryBD extracted 1 program update from this document → INKT pipeline
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly reportBD extracted 1 program update from this document → INKT pipeline
- Aug 6, 2026ReleaseMiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
- Aug 6, 2026ReleaseMiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research SymposiumBD extracted 1 program update from this document → INKT pipeline
- Jun 23, 20268-KCurrent report: shareholder vote
- May 15, 20268-KCurrent report: results of operations · EX-99.1
- May 15, 202610-QQuarterly report
- Apr 30, 2026DEF 14AProxy statement
- Mar 31, 20268-KCurrent report: results of operations · EX-99.1
- Mar 31, 202610-KAnnual report
- Mar 27, 20268-KCurrent report: other events
- Mar 19, 20268-KCurrent report: officer / director change
2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 13, 2026S-8Employee plan registration
- Apr 30, 2026ARSAnnual report to shareholders